Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Retinitis Pigmentosa
Biotech
MeiraGTx gifts last of gene therapy rights to J&J for $415M
MeiraGTx has handed off the remaining interests for a rare disease gene therapy to Johnson & Johnson in a deal that could reach $415 million.
Annalee Armstrong
Dec 21, 2023 10:14am
ProQR, Théa ink new pact for eye assets after old one collapsed
Dec 8, 2023 11:01am
Nanoscope's gene therapy boosts vision function in phase 2 test
Mar 30, 2023 11:04am
J&J links gene therapy to improved vision in early-phase trial
Oct 3, 2022 8:00am
Drug for alcoholics might be the key to vision treatment
Mar 18, 2022 2:08pm
Second Sight slashes support for 'bionic eyes': report
Feb 17, 2022 11:48am
